Literature DB >> 31010953

Preparing for PrEP: estimating the size of the population eligible for HIV pre-exposure prophylaxis among men who have sex with men in England.

Holly D Mitchell1, Sarika Desai1, Hamish Mohammed2, Koh Jun Ong1, Martina Furegato1, Victoria Hall1, Monica Desai1, John Michael Saunders1,3, Gwenda Hughes1, Nigel Field1,4, O Noel Gill1.   

Abstract

OBJECTIVES: The size of the population of men who have sex with men (MSM) who may be eligible for HIV pre-exposure prophylaxis (HIV-PrEP) in England remains unknown. To plan for a national PrEP implementation trial, we estimated the number of MSM attending sexual health clinics (SHCs) that may be eligible for HIV-PrEP in England.
METHODS: Sexually transmitted infection (STI) surveillance data from 2010 to 2015 from the GUMCAD surveillance system were used to estimate the annual number of HIV-negative MSM who may be eligible for HIV-PrEP in England. Based on national eligibility criteria, we identified HIV-negative MSM attending SHCs with a HIV-negative test in the past year and used diagnosed bacterial STI (past year) in this group as a proxy for condomless sex and eligibility for HIV-PrEP. We estimated HIV incidence per 100 person-years (py) in these groups in 2014.
RESULTS: During 2010-2015, the number of HIV-negative MSM attending SHCs with a HIV-negative test in the past year doubled from 14 643 to 29 023, and HIV incidence in this group was 1.9 (95% CI 1.6 to 2.2) per 100 py in 2014. In the same period, the subgroup with a bacterial STI diagnosis (past year), and therefore considered potentially eligible for HIV-PrEP in this analysis, increased from 4365 (30%) to 10 276 (35%). HIV incidence in this subgroup was 3.3 (95% CI 2.7 to 4.0) per 100 py in 2014.
CONCLUSIONS: In 2015, approximately 10 000 HIV-negative MSM were considered potentially eligible for HIV-PrEP based on clinic history in GUMCAD. These data were used to inform the initial recruitment target for the PrEP Impact Trial and will inform future evaluations at a population level. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  HIV; gay men; policy; public health; surveillance

Mesh:

Year:  2019        PMID: 31010953     DOI: 10.1136/sextrans-2019-054009

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  4 in total

1.  PrEP use and unmet PrEP-need among men who have sex with men in London prior to the implementation of a national PrEP programme, a cross-sectional study from June to August 2019.

Authors:  Dana Ogaz; Louise Logan; Tyrone J Curtis; Lorraine McDonagh; Luis Guerra; Daniel Bradshaw; Poorvi Patel; Chiara Macri; Gary Murphy; O Noel Gill; Anne M Johnson; Anthony Nardone; Fiona Burns
Journal:  BMC Public Health       Date:  2022-06-03       Impact factor: 4.135

2.  Analysis of homosexual behavior characteristics and influencing factors of male college students in Zhejiang Province.

Authors:  Zhongrong Yang; Weiyong Chen; Meihua Jin; Wanjun Chen; Xin Zhou; Hui Wang; Lin Chen; Tingting Jiang
Journal:  Medicine (Baltimore)       Date:  2021-07-30       Impact factor: 1.817

3.  Estimated Number of Men Who Have Sex With Men With Indications for HIV Pre-exposure Prophylaxis in a National Sexual Network Study.

Authors:  Kevin M Weiss; Pragati Prasad; Ramya Ramaraju; Maria Zlotorzynska; Samuel M Jenness
Journal:  J Acquir Immune Defic Syndr       Date:  2020-05-01       Impact factor: 3.771

4.  High Rates of Pre-exposure Prophylaxis Eligibility and Associated HIV Incidence in a Population With a Generalized HIV Epidemic in Rakai, Uganda.

Authors:  Victor Ssempijja; Gertrude Nakigozi; Robert Ssekubugu; Joseph Kagaayi; Godfrey Kigozi; Fred Nalugoda; Betty Nantume; James Batte; Grace Kigozi; Ping Teresa Yeh; Hadijja Nakawooya; David Serwadda; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Kate M Grabowski; Larry W Chang; Anja Van't Hoog; Frank Cobelens; Steven J Reynolds
Journal:  J Acquir Immune Defic Syndr       Date:  2022-03-08       Impact factor: 3.771

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.